title: Identifying vaccine targets for anti-leishmanial vaccine development.
abstract: Leishmaniasis is a neglected tropical disease spread by an arthropod vector. It remains a significant health problem with an incidence of 0.2–0.4 million visceral leishmaniasis and 0.7–1.2 million cutaneous leishmaniasis cases each year. There are limitations associated with the current therapeutic regimens for leishmaniasis and the fact that after recovery from infection the host becomes immune to subsequent infection therefore, these factors force the feasibility of a vaccine for leishmaniasis. Publication of the genome sequence of Leishmania has paved a new way to understand the pathogenesis and host immunological status therefore providing a deep insight in the field of vaccine research. This review is an effort to study the antigenic targets in Leishmania to develop an anti-leishmanial vaccine.
authors.forename: Shyam
authors.initials: S
authors.lastname: Sundar
authors.forename: Bhawana
authors.initials: B
authors.lastname: Singh
mesh_terms: D000953:Antigens, Protozoan / Q000235:genetics / Q000276:immunology*; D055808:Drug Discovery / Q000379:methods / Q000639:trends; D018503:Genome, Protozoan; D006801:Humans; D007891:Leishmania / Q000276:immunology*; D007896:Leishmaniasis / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control* / Q000635:transmission; D054332:Leishmaniasis Vaccines / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification*
chemical_list: D000953:Antigens, Protozoan; D054332:Leishmaniasis Vaccines